Osteopenia in young hypogonadal women with systemic lupus erythematosus receiving chronic steroid therapy: A randomized controlled trial comparing calcitriol and hormonal replacement therapy

Rheumatology

Volumn 38, Issue 12, 1999, Pages 1239-1244

  Kung, A W C ^a   Chan, T M ^a   Lau, C S ^a   Wong, R W S ^a   Yeung, S S C ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Calcitriol; Hormonal replacement therapy; Osteopenia; SLE; Steroid; Young hypogonadal women

Indexed keywords

CALCITRIOL; CALCIUM CARBONATE; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE ACETATE; OSTEOCALCIN; PREDNISONE; STEROID;

ADULT; ARTICLE; BLOOD LEVEL; BONE DENSITY; BONE MINERAL; CASE REPORT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LUMBAR SPINE; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; RANDOMIZED CONTROLLED TRIAL; STEROID THERAPY; SYSTEMIC LUPUS ERYTHEMATOSUS; TIME;

EID: 0032778081     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.12.1239     Document Type: Article

References (30)

1. Lukert BP, Raisz LG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am 1994;20:629-51.
2. Kimberg DV, Baerg RD, Gerson E et al. Effect of cortisone treatment on the active transport of calcium by the small intestine. J Clin Invest 1971;50:1309-21.
3. Lukert BP, Adams JS. Calcium and phosphorus homeostasis in man. Effect of corticosteroids. Arch Intern Med 1976;136:1249-53.
4. Suzuki Y, Ichikawa Y, Saito E et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983;32:151-6.
5. Hsueh AJ, Erickson GF. Glucocorticoid inhibition of FSH-induced estrogen production in cultured rat granulosa cells. Steroids 1978;32:639-48.
6. Meunier PJ, Dempster DW, Edouard C et al. Bone histomorphometry in corticosteroid-induced osteoporosis and Cushing's syndrome. Adv Exp Med Biol 1974;171:191.
7. Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-82.
8. Lane NE, Lubert B. The science and therapy of glucocorticoid-induced bone loss. Endocrinol Metab Clin North Am 1998;27:465-83.
9. LoCascio V, Bonucci E, Imbimbo B et al. Bone loss after glucocorticoid therapy. Calcif Tissue Int 1984;36:435.
10. Eastell R, Reid DM, Compston J, Cooper C, Fogelman I, Francis RM et al. A UK Consensus Group on management of glucocorticoid-induced osteoporosis: an update. J Intern Med 1998;244:271-92.
11. American College of Rheumatology Task Force on Osteoporosis Guidelines. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheum 1996;39:1791-1801.
12. Lukert BP, Johnson BE, Robinson RG. Estrogen and progesterone replacement therapy reduces glucocorticoidinduced bone loss. J Bone Miner Res 1992;7:1063-9.
13. Lane NE, Pressman AR, Star VL, Cummings SR, Nevitt MC. Rheumatoid arthritis and bone mineral density in elderly women. J Bone Miner Res 1995;10:257-63.
14. Barrett C, Neylor N, Snaith M. Estrogen-induced systemic lupus erythematosus. Br J Rheumatol 1986;25:300-1.
15. Healey J, Paget S, Williams-Russo P et al. Randomized trial of salmon calcitonin to prevent bone loss in corticosteroid treated temporal arthritis and polymyalgia rheumatica. Calcif Tissue Int 1996;58:73-80.
16. Avioli LV. The role of calcitonin in the prevention of osteoporosis. Endocrinol Metab Clin North Am 1998; 27:411-8.
17. Gennari C, Camporeale A. Calcitonin in the treatment of osteoporosis. Osteoporos Int 1997;7(Suppl. 3):S159-62.
18. Saag KG, Emkey R, Schnitzer TJ, Brown JP, Hawkins F, Goemaere S et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. N Engl J Med 1998;339:292-9.
19. Adachi JD, Bensen WG, Brown J, Handley D, Hodsman A, Josse R et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med 1997; 337:382-7.
20. Sambrook P, Birmingham J, Kelly P et al. Prevention of corticosteroid osteoporosis: a comparison of calcium calcitriol and calcitonin. N Engl J Med 1993;328:1747-52.
21. Tan EM, Cohen AS, Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematous. Arthritis Rheum 1982;25:1271-7.
22. Hall GM, Daniels M, Doyle DV et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients with and without steroids. Arthritis Rheum 1994;37:1499-1505.
23. Lane NE, Roe B, Genant HK, Arnard C. Parathyroid hormone treatment reverses glucocorticoid-induced osteoporosis: results of a randomised controlled trial. Arthritis Rheum 1997;40(Suppl. 1):324.
24. Adachi JD, Benson WG, Blanchi F et al. Calcium and vitamin D supplementation prevents bone loss in the spine secondary to low dose corticosteroids. J Rheumatol 1996;125:995-1000.
25. Buckley LM, Leib ES, Cartularo KS et al. Calcium and vitamin D, supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. Ann Intern Med 1996;125: 961-8.
26. Dyksman TR, Haralson KM, Gluck OS et al. Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984;27:1336-43.
27. Ott SM, Chesnut III CH. Tolerance to doses of calcitriol is associated with improved bone density in women with postmenopausal osteoporosis [abstract no. 449]. J Bone Miner Res 1990;5(Suppl. 2):186.
28. Need AG, Morris HA, Horowitz M, Nordin BE. The response to calcitriol therapy in postmenopausal osteoporotic women is a function of initial calcium absorptive status. Calcif Tissue Int 1997;61:6-9.
29. Kung AWC, Luk K, Chu LW, Chiu P. Age-related osteoporosis in Chinese: an evaluation of the response of intestinal calcium absorption and calcitrophic hormones to dietary calcium deprivation. Am J Clin Nutr 1998;68:1291-7.
30. Chesnut CH, Bell NH, Clark GS, Drinkwater BL, English SC, Johnston CC et al. Hormonal replacement therapy in postmenopausal women: urinary N-telopeptide of type 1 collagen monitors therapeutic effect and predicts response of bone mineral density. Am J Med 1997;102:29-37.